Nektar Therapeutics
$ 81.26
1.01%
14 Apr - close price
- Market Cap 2,331,184,000 USD
- Current Price $ 81.26
- High / Low $ 81.43 / 78.12
- Stock P/E N/A
- Book Value 4.41
- EPS -9.73
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -2.18 %
- 52 Week High 81.43
- 52 Week Low 7.99
About
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Analyst Target Price
$128.12
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-13 | 2025-11-06 | 2025-08-08 | 2025-05-07 | 2025-03-03 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-04 | 2023-11-07 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -1.2898 | -1.87 | -2.95 | -0.2404 | -0.15 | -0.18 | -0.25 | -0.19 | -0.22 | -0.24 | -0.27 | -0.32 |
| Estimated EPS | -3.495 | -0.1928 | -0.2 | -0.19 | -0.195 | -0.21 | -0.2 | -0.19 | -0.21 | -0.2 | -0.28 | -0.25 |
| Surprise | 2.2052 | -1.6772 | -2.75 | -0.0504 | 0.045 | 0.03 | -0.05 | 0 | -0.01 | -0.04 | 0.01 | -0.07 |
| Surprise Percentage | 63.0959% | -869.917% | -1375% | -26.5263% | 23.0769% | 14.2857% | -25% | 0% | -4.7619% | -20% | 3.5714% | -28% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.84 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NKTR
2026-04-14 15:39:49
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Nektar Therapeutics (NASDAQ: NKTR) for alleged federal securities law violations. The lawsuit claims that Nektar made false and misleading statements regarding the REZOLVE-AA trial, specifically that enrollment did not follow protocol and its integrity was overstated. Investors who purchased Nektar securities between February 26, 2025, and December 25, 2025, are encouraged to join the suit, with a lead plaintiff deadline of May 5, 2026.
2026-04-14 15:39:49
Bernstein Liebhard LLP warns Nektar Therapeutics (NASDAQ: NKTR) investors about an upcoming deadline for a securities fraud class action lawsuit. Investors who purchased shares between February 26, 2025, and December 15, 2025, and experienced losses, are encouraged to contact the firm to discuss their rights. The lawsuit alleges misrepresentations concerning the Phase 2b trial for REZOLVE-AA, with a lead plaintiff deadline of May 5, 2026.
2026-04-14 12:39:49
The Gross Law Firm has issued a shareholder alert for investors in Nektar Therapeutics (NASDAQ: NKTR), encouraging those who suffered losses during the class period of February 26, 2025, to December 15, 2025, to contact them. The lawsuit alleges that Nektar made materially false or misleading statements regarding the REZOLVE-AA trial, specifically that enrollment did not follow protocol and that its integrity and prospects were overstated. Investors have until May 5, 2026, to seek lead plaintiff appointment.
2026-04-14 08:00:00
Holzer & Holzer, LLC has announced lead plaintiff deadlines for shareholder class action lawsuits against Aquestive Therapeutics, Inc. (AQST), Nektar Therapeutics (NKTR), and Eos Energy Enterprises, Inc. (EOSE). Investors who suffered losses in these companies during specified periods are encouraged to contact the firm to discuss their legal rights and seek appointment as lead plaintiff before the deadlines on May 4 and May 5, 2026. The lawsuits allege that the companies made materially false and misleading statements or failed to disclose material facts.
2026-04-13 19:39:01
Levi & Korsinsky, LLP has issued an investor alert regarding Nektar Therapeutics (NASDAQ: NKTR) for alleged securities fraud. Institutional investors who held NKTR shares between February 26, 2025, and December 15, 2025, may have suffered losses due to misleading statements about patient eligibility in a clinical trial. The firm is encouraging affected investors to consider leading a class action lawsuit, with a lead plaintiff filing deadline of May 5, 2026.
2026-04-13 14:39:01
The Portnoy Law Firm has announced a class action lawsuit against Nektar Therapeutics, Inc. on behalf of investors who purchased securities between February 26, 2026, and December 12, 2025. The lawsuit alleges Nektar made misleading statements regarding its Phase 2b REZOLVE-AA trial, which "narrowly missed statistical significance" and included disqualified patients, causing a significant stock price drop. Investors have until May 5, 2026, to file a lead plaintiff motion.
